Pharmacokinetic model-driven remifentanil administration in the morbidly obese: The 'critical weight' and the 'fictitious height', a possible solution to an unsolved problem?

Clinical Pharmacokinetics

Volumn 48, Issue 6, 2009, Pages 397-398

  La Colla, L ^a,d   Albertin, A ^b   La Colla, G ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

REMIFENTANIL;

BODY HEIGHT; BODY WEIGHT; EXPERIMENTAL MODEL; HUMAN; INFUSION PUMP; LEAN BODY WEIGHT; MATHEMATICAL ANALYSIS; NOTE; OBESITY; PRIORITY JOURNAL;

BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; HUMANS; ITALY; MODELS, BIOLOGICAL; OBESITY, MORBID; PIPERIDINES; PROBLEM SOLVING;

EID: 68249136890     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948060-00005     Document Type: Note

References (5)

1. La Colla L, Albertin A, La Colla G, et al. Target controlled infusion of remifentanil: beware when using it in morbidly obese patients. First World Congress of Total Intravenous Anesthesia - TCI; 2007 Sep 27-29; Venice
2. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil: I. Model development. Anesthesiology 1997; 86: 10-23
3. James WPT, Waterlow JC. UK Department of Health and Social Security/Medical Research Council Group on Obesity Research. Research on obesity: a report of theDHSS/MRCGroup. London:HMSO[Her Majesty's Stationery Office], 1976
4. Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743-4
5. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65